Allogene Therapeutics ALLO Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's financing cash flow?
- Allogene Therapeutics (ALLO) reported financing cash flow of $21.12M in Q1 2026.
- How has Allogene Therapeutics's financing cash flow changed year-over-year?
- Allogene Therapeutics's financing cash flow increased by 51.0% year-over-year, from $13.99M to $21.12M.
- What is the long-term trend for Allogene Therapeutics's financing cash flow?
- Over 4 years (2021 to 2025), Allogene Therapeutics's financing cash flow has grown at a 26.0% compound annual growth rate (CAGR), from $11.96M to $30.16M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.